The Mpox Vaccine, MVA-BN, Receives Approval for Use in Adolescents 12 - 17 years of age

Featured News
The mpox virus under a microscope

MVA-BN was approved by the European Medicines Agency (EMA) today for use against Mpox and smallpox in adolescents 12-17 years of age. This is of huge importance given the current Mpox outbreak has yet to be controlled and has disproportionately impacted children. Dr. Diemert and the GW VRU team are proud to have contributed critical clinical research needed to get this vaccine approved for this vital vulnerable population.

Click here to read the press release on the Mpox vaccine approval for adolescents
Mpox

Latest News

Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial
Latest news about the results of the COVAIL trial regarding the Sanofi booster. GW participated as one of the many sites for this COVID-19 vaccine study.
Pfizer's RSV vaccine, Abrysvo, has shown a strong immune response and well-tolerated safety profile in new study.
Our Deputy Director, Dr. Elissa Malkin, was a part of the Pfizer's newest study on its respiratory syncytial virus (RSV) vaccine, Abrysvo, which has shown to have a strong immune response in adults 18+.
Young child smiling with his armed raised. There is a band-aid are the arm to indicate that he has received a vaccination.
Check out the CDC's new report titled 'Health and Economic Benefits of Routine Childhood Immunizations in the Era of the Vaccines for Children Program - United States, 1994 - 2023
The CDC has released a new report on the health and economic benefits of routine childhood immunizations since the creation of the Vaccines for Children (VFC) program in 1994.